Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 362 for “"Checkpoint Inhibitors"”.

  1. Characterising peripheral responses to immune checkpoint inhibitors

    <p>The introduction of immune checkpoint blockade (ICB) therapy for metastatic melanoma (MM) has dramatically improved survival in this patient group. However, only some patients experience durable clinical response, and many will develop immune-related adverse events (irAEs). The identification of …

    oxford Repository record for Characterising peripheral responses to immune checkpoint inhibitors (opens in a new tab)

  2. Reversing AML microenvironment-mediated immunosuppression using immune checkpoint inhibitors

    … AML cells, as well as the effect of using immune checkpoint inhibitors in reversing the suppressed T lymphocyte activity. Methods: The in vitro 3D biomimetic matrix model was developed using patient-derived bone marrow mesenchymal stromal cells (BM-MSC), AML cells, and peripheral blood mononuclear …

    ku Repository record for Reversing AML microenvironment-mediated immunosuppression using immune checkpoint inhibitors (opens in a new tab)

  3. G₂ DNA damage checkpoint : inhibitors and there potential for anticancer treatment

    … by activation of DNA repair mechanisms and of checkpoints that delay cell cycle progression to allow more time for DNA repair. G₂ checkpoint inhibitors can force cells arrested in G₂ phase by DNA damage to enter mitosis thereby enhancing the killing of cancer cells by DNA-damaging approaches. …

    ubc Repository record for G₂ DNA damage checkpoint : inhibitors and there potential for anticancer treatment (opens in a new tab) Download PDF for G₂ DNA damage checkpoint : inhibitors and there potential for anticancer treatment (opens in a new tab)

  4. Development and Optimization of Immune Checkpoint Inhibitors Using a Canine Model

    … Another class of immunotherapeutic drugs are checkpoint inhibitors. These drugs can enhance the immune response towards cancer cells and allow for a more targeted destruction of cancer cells, decreasing the severity of adverse side effects suffered by cancer patients. Approved checkpoint …

    ku Repository record for Development and Optimization of Immune Checkpoint Inhibitors Using a Canine Model (opens in a new tab)

  5. Impact of Concurrent Antibiotic & Corticosteroid Use on Efficacy of Immune Checkpoint Inhibitors

    … only 20% of patients responded to immune checkpoint inhibitors (ICI). Patients with NSCLC often have infections which are treated with antibiotics. Corticosteroids are also used to treat NSCLC-related conditions. However, previous studies have suggested antibiotic and corticosteroid …

    umn Repository record for Impact of Concurrent Antibiotic & Corticosteroid Use on Efficacy of Immune Checkpoint Inhibitors (opens in a new tab)

  6. Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors

    … fatal, side effect of immune check- point inhibitors (ICIs), a class of cancer therapies. Despite extensive experimental work on the causes, development, and progression of this disease, much still remains unknown about the importance of the different immunological pathways involved. To …

    oxford Repository record for Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors (opens in a new tab)

  7. Tarloxotinib amplifies the anti-tumour efficacy of immune checkpoint inhibitors through multiple mechanisms

    … to suppress anti-tumour immune responses. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that function by blocking the inhibitory interactions between these immunosuppressive molecules, thereby relieving T-cells from negative regulation. This therapeutic approach is capable of …

    auckland-ms Repository record for Tarloxotinib amplifies the anti-tumour efficacy of immune checkpoint inhibitors through multiple mechanisms (opens in a new tab)

  8. Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors

    … previous studies have demonstrated that immune checkpoint inhibitors have a robust anti-tumor efficacy by augmenting the T cell response to the tumor cells. Thus, immune checkpoint inhibitors were combined with D2C7-IT in order to enhance the immunotoxin-induced anti-tumor immune response to …

    duke Repository record for Immunotoxin Monotherapy and Combinatorial Therapy With Immune Checkpoint Inhibitors for Malignant Brain Tumors (opens in a new tab)

  9. Delineation of mechanisms underlying the development of irAEs upon immune checkpoint inhibitors immunotherapy

    Ο κρίσιμος ρόλος του ανοσοποιητικού συστήματος στην εξάλειψη των καρκινικών κυττάρων έχει αναγνωριστεί εδώ και καιρό, μια διαδικασία γνωστή ως ανοσοεπιτήρηση. Ωστόσο, ο καρκίνος εξακολουθεί να αποτελεί σημαντική πρόκληση, καθώς μπορεί να αξιοποιήσει πολλούς μηχανισμούς για να αποφύγει τις …

    athens Repository record for Delineation of mechanisms underlying the development of irAEs upon immune checkpoint inhibitors immunotherapy (opens in a new tab)

  10. Longitudinal Monitoring of Tumor Response to Immune Checkpoint Inhibitors using Diffuse Optical Spectroscopy

    Immune checkpoint drugs have completely changed the way people treat metastatic melanoma and non-small-cell lung cancer. While the impacts of these immunological checkpoints and their suppression on T cell function are well characterized, their consequences on the tumor microenvironment are not. In …

    arkansas Repository record for Longitudinal Monitoring of Tumor Response to Immune Checkpoint Inhibitors using Diffuse Optical Spectroscopy (opens in a new tab)

  11. Implementing Evidence Based Guidelines For Immune Checkpoint Inhibitors In A Community Oncology Clinic

    … patient safety for patient's receiving immune checkpoint inhibitor therapy by implementing evidenced based guidelinesBackground: Immuno-oncology (I/O) is a growing field in oncology. Immune checkpoint inhibitors (ICIs) are the most common type of I/O. Side effects from ICI differ from …

    hawaii Repository record for Implementing Evidence Based Guidelines For Immune Checkpoint Inhibitors In A Community Oncology Clinic (opens in a new tab)

  12. Immune-Related Adverse Events (irAEs) of Immune Checkpoint Inhibitors (ICIs) in Advanced Melanoma Patients

    Abstract (1): Background: The use of ipilimumab, nivolumab, and pembrolizumab as monotherapies or in combination has transformed the management of advanced melanoma even though these drugs are associated with a new profile of immune-related adverse events (irAEs). The incidence of irAEs from …

    arizona-thes Repository record for Immune-Related Adverse Events (irAEs) of Immune Checkpoint Inhibitors (ICIs) in Advanced Melanoma Patients (opens in a new tab)

  13. RE-ANALYSIS OF DEFINED BACTERIA CONSORTIA’S IMPACT ON IMMUNE CHECKPOINT INHIBITORS RESPONSE IN MURINE MODELS

    Immune checkpoint inhibitors (ICI) have revolutionized the cancer treatment across all types of tumors, but only 10-30% patients have durable responses. Gut microbiome has shown potential to be a biomarker in predicting tumor responses. Several preclinical and clinical studies have previously …

    jhu Repository record for RE-ANALYSIS OF DEFINED BACTERIA CONSORTIA’S IMPACT ON IMMUNE CHECKPOINT INHIBITORS RESPONSE IN MURINE MODELS (opens in a new tab)

  14. Novel G2 cell cycle checkpoint inhibitors and antimitotic agents isolated through two new HTS bioassays

    … was to discover structurally novel G2 cell cycle checkpoint inhibitors and antimitotic agents in natural product extracts. Active crude extracts were identified via high throughput bioassays for G2 checkpoint inhibitors and antimitotic agents. The assays were developed by our collaborator Michel …

    ubc Repository record for Novel G2 cell cycle checkpoint inhibitors and antimitotic agents isolated through two new HTS bioassays (opens in a new tab) Download PDF for Novel G2 cell cycle checkpoint inhibitors and antimitotic agents isolated through two new HTS bioassays (opens in a new tab)

  15. Discovery and delivery of peptide-based immune checkpoint inhibitors targeting Pd-L1 for cancer immunotherapy

    … dissertation is to develop peptide-based immune checkpoint inhibitors that block the interaction between programmed cell death ligand-1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) for cancer immunotherapy. We recently discovered a low-molecular-weight linear anti-PD-L1 peptide …

    umkc Repository record for Discovery and delivery of peptide-based immune checkpoint inhibitors targeting Pd-L1 for cancer immunotherapy (opens in a new tab)

  16. Approach using "second-generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer

    … the blockade of novel “second generation” immune checkpoints could be promising to enhance the number of responders. This project aims at highlighting new immune checkpoints of particular interest in the context of TNBC and studying the impact of their inhibition on TNBC progression. To this end, …

    liege Repository record for Approach using "second-generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer (opens in a new tab) Restricted access

  17. Estimating Heterogeneity of Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

    … will benefit and who will be harmed by immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC) are poorly understood and lead to sub-optimal outcomes. Evidence gaps can be filled using real world data (RWD) from the broad population of ICI users, including high-risk …

    jhu Repository record for Estimating Heterogeneity of Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (opens in a new tab)

  18. Blood-Brain-Barrier Penetrating TGFβ Traps for Treatment of Glioblastoma in Combination with Immune Checkpoint Inhibitors

    … to treat glioblastoma. Among them, immune checkpoint signaling inhibition has established a leading role among the immunomodulatory therapies. Brain tumor associated immune suppression is considered to be mediated by transforming growth factor β (TGFβ) while deficiency of response to immune …

    jhu Repository record for Blood-Brain-Barrier Penetrating TGFβ Traps for Treatment of Glioblastoma in Combination with Immune Checkpoint Inhibitors (opens in a new tab)

Page 1 of 19